Habataki Welfare Project

Email

info@habataki.gr.jp

Phone

T: +81 3 5228 1200

Web

http://www.habatakifukushi.jp

Address

Shin-ogawamachi Bldg 5F, Shin-ogawamachi 9-20, Shinjuku Shinjuku Tokyo 162-0814 Japan
About Habataki Welfare Project

Habataki is a unique social welfare organization in Japan, which engages in activities to stop a recurrence of drug-induced disaster. We continue to provide information and support for hemophilia patients and their family

Our vision

  • Improve medical services, welfare and social life for hemophilia patients with HIV in Japan. 
  • Contribute public welfare and medical care to hemophilia community.
  • Stop a recurrence of drug-induced disaster.

Our activities

  • Counseling services: We respond to the obstacles and problems faced by victims and their family.
  • Research projects: We support health and life in patients by investigating/solving their present facts.
  • Education and enlightenment program: We carry on activities to eliminate the prejudice and discrimination towards HIV from the tragic experience of HIV-tainted blood scandal.

Our motto

When the patients get a positive frame of mind, medical system will also certainly change the attitude.

We make efforts to create a society where everyone protects our life and health. We respect each individual’s presence. And our activities are based on two points as follows:

1) We hope that we will achieve a society where each individual esteems their life.

2) We hope that the patient will make life independently. On the background of good quality of medical care and welfare, we continuously work our daily tasks with volunteer, company, non-profit organization (NPO) and administrative agency in order to obtain the idea that physically and mentally challenged individuals live comfortably in this society.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close